Direct intralymphatic injection of peptide vaccines enhances immunogenicity

Johansen, P. et al. (2005) Direct intralymphatic injection of peptide vaccines enhances immunogenicity. European Journal of Immunology, 35(2), pp. 568-574. (doi: 10.1002/eji.200425599) (PMID:15682446)

Full text not currently available from Enlighten.


Research to enhance the efficiency of vaccines focuses mainly on improving either the adjuvant or the type and form of the antigen. This study evaluates the influence of the administration route on the efficiency of a peptide-based vaccine. Peptide vaccines are generally administered subcutaneously or intradermally, from where they must reach secondary lymphatic organs to induce an immune response. We analyzed the efficacy of peptide vaccines administered directly into a lymph node. Using a MHC class I-binding peptide from lymphocytic choriomeningitis virus, we found that intralymphatic injection enhanced immunogenicity by as much as 10(6) times when compared to subcutaneous and intradermal vaccination. Intralymphatic administration induced CD8 T cell responses with strong cytotoxic activity and IFN-gamma production that conferred long-term protection against viral infections and tumors. These results should have immediate implications for clinical immunotherapy of infectious disease and cancer.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Maloy, Professor Kevin
Authors: Johansen, P., Häffner, A.C., Koch, F., Zepter, K., Erdmann, I., Maloy, K., Simard, J.J., Storni, J.J., Senti, G., Bot, A., Wüthrich, B., and Kündig, T.M.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:European Journal of Immunology
ISSN (Online):1521-4141
Published Online:28 January 2005

University Staff: Request a correction | Enlighten Editors: Update this record